Table 2. The distributions of serum tumor markers according to tumor stage, histology and EGFR mutation.

	CEA Median (range)	CEA > 5 ng/ml (%)	CFRA 21-1 Median (range)	CYFRA21-1> 3.3 ng/ml (%)	SCCA Median (range)	SCCA > 1.5 ng/ml (%)	NSE Median (range)	NSE > 15.2 ng/ml (%)
All patients (n = 1016)Histology
Adenocarcinoma	3.42 (0.33–959.6)	209 (36.9)	2.65 (0.30–138.2)	181 (32.0)	0.70 (0.10–29.53)	41 (7.2)	13.73 (1.03–112.04)	155 (27.4)
Squamous cell carcinoma	3.20 (0.20–499.8)	95 (27.0)	4.18 (0.30–936.0)	228 (64.8)	1.10 (0.10–58.40)	126 (35.8)	14.81 (0.90–59.72)	153 (43.5)
Large cell lung carcinoma	3.74 (0.66–52.20)	16 (38.1)	3.09 (1.02–10.26)	16 (38.1)	1.00 (0.40–14.50)	9 (21.4)	14.54 (8.96–28.01)	16 (38.1)
Adenosquamous carcinoma	6.24 (1.37–260.8)	12 (63.2)	0.80 (0.10–58.40)	5 (13.5)	0.80 (0.10–10.30)	3 (15.8)	16.21 (12.76–29.91)	12 (63.2)
Others	2.26 (0.56–14.96)	8 (21.6)	2.28 (0.46–61.33)	14 (73.7)	0.80 (0.10–40.94)	3 (8.1)	14.26 (6.41–26.92)	15 (40.5)
Clinical stage
I	2.93 (0.20–283.3)	129 (25.4)	2.75 (0.30–936.0)	172 (33.9)	0.80 (0.10–58.40)	63 (12.4)	13.67 (0.90–112.04)	140 (27.6)
II	3.54 (0.60–389.5)	71 (35.9)	3.93 (0.30–71.59)	120 (60.6)	0.90 (0.10–54.70)	61 (30.8)	14.68 (1.77–67.90)	85 (42.9)
IIIA	4.43 (0.42–959.6)	140 (45.2)	3.26 (0.46–138.2)	152 (49.0)	0.80 (0.10–32.00)	58 (18.7)	14.54 (1.03–86.17)	126 (40.6)
Total	3.30 (0.20–959.6)		3.06 (0.30–936.0)		0.80 (0.10–58.40)		14.24 (0.90–112.04)
AD patients (n = 566)Mutation status
EGFR-mutated	3.48 (0.33–959.6)	86 (39.4)	2.50 (0.74–138.2)	68 (31.2)	0.60 (0.10–22.75)	12 (5.5)	14.27 (1.77–112.04)	70 (32.1)
EGFR wild-type	3.40 (0.42–389.5)	123 (35.3)	2.68 (0.30–43.32)	113 (32.5)	0.70 (0.10–29.53)	29 (8.3)	13.25 (1.03–86.17)	85 (24.4)
Total	3.42 (0.33–959.6)	209 (36.9)	2.65 (0.30–138.2)	181 (32.0)	0.70 (0.10–29.53)	41 (7.2)	13.73 (1.03–112.04)	155 (27.4)